2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2016 Featured Talks » Revisiting matrix metalloproteinases: allosteric inhibition of MMP9 using a monoclonal antibody



Revisiting matrix metalloproteinases: allosteric inhibition of MMP9 using a monoclonal antibody


Victoria Smith, PhD
Gilead Sciences








Victoria Smith, PhD
Senior Director, Biology
Dept Biologics and Target Biology
Gilead Sciences Inc.


Dr Smith has 20 years of experience in target discovery and translational research in biotechnology. At Gilead, Dr Smith leads the Biologics group which drives discovery and provides clinical support for antibody therapeutics across diverse therapeutic areas. Prior to the acquisition of Arresto by Gilead in 2011, she was the Vice President of Research and Pre-clinical Development at Arresto Biosciences Inc., where she lead research efforts resulting in the development and clinical entry of a first-in-class novel antibody therapeutics targeting extracellular matrix enzymes LOXL2 and MMP9. Prior to Arresto, Dr Smith was a Senior Scientist in Research at Genentech Inc., where she was involved with a variety of different programs including target discovery, disease profiling, and development of antibody therapeutics for oncology. She received a BSc with Honors from the University of Western Australia with majors in Physical and Inorganic Chemistry and Biochemistry and a Ph.D. in Biology from the University of Cambridge, United Kingdom. She was awarded a Human Frontier’s fellowship for her postdoctoral studies on high-throughput functional genomics at Stanford University. Dr Smith has authored many publications along with numerous patents covering antibody therapeutics for oncology, fibrosis and inflammatory diseases, target discovery, and novel methodologies.